Sciformix to enter European pharma sector with UK office

Scientific process organisation Sciformix Corporation has opened a new office in Manchester, UK, marking its entry to the European market.

For seven years, Sciformix has worked with life science organisations on safety and risk management, regulatory affairs and operations and clinical research and post-approval support.    

The expansion into Europe joins the ranks of its operations in the United States and Asia, now with over 750 employees. With delivery functions operating also out of the European Union (EU), clients will experience Sciformix even more as an extension of their own operations.  

Industry groups have lobbied the UK government to help establish and nurture a life sciences hub, similar to that in Boston, USA where world-class research institutions abut promising biotech start-ups and Big Pharma.

Manish Soman, President & CEO, Sciformix Corporation commented, “Sciformix’s long term strategy focuses on evolving and enhancing our service and technology offerings, broadening our global reach and growing and diversifying the client and revenue base. Building a European hub will support all of these objectives. With our clients’ growth in emerging markets, it has become increasingly important for us to truly understand the local safety and regulatory challenges our clients face and to become the partner of choice when it comes to outsourcing these activities. Sciformix is such a trusted provider.”  

The new office will support all service lines, however, the initial focus will be on consulting, safety and risk management, regulatory, and labelling services.